IQVIA Holdings, Inc.
IQV
$256.05
+2.72%
IQVIA Holdings Inc. is a global leader in clinical research and technology solutions for the life science industry, formed in 2016 from the merger of Quintiles and IMS Health. It provides outsourced clinical development services, healthcare data analytics, and commercialization solutions to biopharmaceutical firms, providers, payers, and policymakers. The company is distinct as a one-stop-shop combining contract research organization (CRO) services with vast healthcare data assets, making it a critical partner in drug development and commercialization. Currently, the investor narrative centers on IQVIA's accelerating revenue growth, driven by strong demand for its research and development solutions, and its ability to leverage AI and advanced analytics to enhance drug development efficiency. Recent stock momentum has been robust, with the shares rallying sharply in July 2026, likely fueled by positive earnings results and a favorable outlook for the healthcare services sector.…
IQV
IQVIA Holdings, Inc.
$256.05
Related headlines
Investment Opinion: Should I buy IQV Today?
Based on the analysis, IQVIA is rated a Buy. The strong buy consensus, with an average target of $275.17, implies 16.3% upside, supported by accelerating revenue growth and expected EPS growth of 42.5%. The forward PE of 16.39x is reasonable given the growth trajectory, and the company's ROE of 20.91% indicates efficient capital use.
Sign up to view all
IQV 12-Month Price Forecast
The AI assessment is bullish, driven by strong growth metrics and analyst optimism. However, confidence is medium due to high leverage and valuation concerns. The stance would be upgraded if revenue growth exceeds 10% and margins improve, or downgraded if growth falls below 5% or debt levels increase.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on IQVIA Holdings, Inc.'s 12-month outlook, with a consensus price target around $275.17 and implied upside of +7.5% versus the current price.
Average Target
$275.17
0 analysts
Implied Upside
+7.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$240 - $300
Analyst target range
The wide target range of $240 to $300 reflects uncertainty about the pace of growth and margin expansion. The high target likely assumes accelerating revenue growth and successful integration of AI-driven analytics, while the low target may price in potential competitive pressures or a slowdown in clinical trial demand. Recent ratings actions show a mix of upgrades and downgrades, with Morgan Stanley downgrading to Equal Weight in June 2026, but TD Cowen and Barclays upgrading in March 2026, suggesting evolving sentiment. The overall strong buy consensus and recent price surge indicate analysts are optimistic about IQVIA's future, but the spread in targets highlights the need for careful monitoring of execution.
Bulls vs Bears: IQV Investment Factors
IQVIA presents a compelling growth story with accelerating revenue, strong earnings expectations, and a strong buy consensus. However, high leverage, low liquidity, and elevated valuation metrics introduce significant risks. The bull case is currently stronger, driven by robust momentum and analyst optimism, but the bear case highlights potential downside if growth decelerates or debt becomes burdensome. The most critical tension is whether IQVIA can sustain its 8%+ revenue growth and expand margins to justify its forward PE of 16.39x, or if competitive pressures and macro headwinds will compress earnings growth.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue grew 8.41% YoY to $4.151B, up from 7.1% in Q1 2025, indicating accelerating demand for R&D solutions. Sequential growth from $4.017B in Q2 2025 to $4.151B in Q1 2026 shows consistent momentum.
- Strong Earnings Growth Expected: Forward PE of 16.39x vs trailing PE of 28.50x implies a 42.5% expected EPS increase, reflecting analyst optimism. Estimated EPS of $20.78 for the next fiscal year supports this growth narrative.
- Analyst Consensus Strong Buy: With 18 analysts, the average target is $275.17, implying 16.3% upside from the current price of $236.66. The recommendation mean of 1.38 (strong buy) indicates broad bullish sentiment.
- Robust Stock Momentum: The stock is up 41.76% over 6 months and 24.95% over 1 year, trading at 94.1% of its 52-week range. This reflects strong market confidence and positive earnings momentum.
Bearish
- High Debt Levels: Debt-to-equity ratio of 2.49x indicates significant leverage, which could strain cash flows if interest rates rise or earnings disappoint. Interest expense of $192M in Q1 2026 is substantial.
- Low Current Ratio: Current ratio of 0.75 suggests potential liquidity concerns, as current liabilities exceed current assets. This could limit financial flexibility in a downturn.
- Elevated Valuation Metrics: PEG ratio of 6.34x and PS ratio of 2.38x are high, suggesting the stock may be overvalued relative to growth. EV/EBITDA of 15.28x is also above historical norms.
- Analyst Target Range Wide: The target price range of $240 to $300 reflects uncertainty, with the low target only 1.4% above current price. This suggests some analysts see limited upside.
IQV Technical Analysis
IQVIA's stock is in a strong uptrend, with a 1-year price change of +24.95% and a 6-month change of +41.76%. The current price of $236.66 sits at 94.1% of its 52-week range (low $154.50, high $251.36), indicating the stock is trading near its highs, reflecting robust momentum and investor confidence. This positioning suggests the market is rewarding the company's growth prospects, though it also raises the risk of short-term overextension.
Beta
1.18
1.18x market volatility
Max Drawdown
-35.9%
Largest decline past year
52-Week Range
$155-$260
Price range past year
Annual Return
+33.3%
Cumulative gain past year
| Period | IQV Return | S&P 500 |
|---|---|---|
| 1m | +27.0% | +1.9% |
| 3m | +52.5% | +2.3% |
| 6m | +54.6% | +10.6% |
| 1y | +33.3% | +19.5% |
| ytd | +13.6% | +11.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IQV Fundamental Analysis
IQVIA's revenue trajectory is accelerating, with Q1 2026 revenue of $4.151 billion, up 8.41% year-over-year, and sequential growth from $4.10 billion in Q3 2025 and $4.017 billion in Q2 2025. The company's Research and Development Solutions segment generated $2.397 billion in revenue, indicating it is the primary growth driver. This growth is supported by strong demand for clinical trial services and data analytics, positioning IQVIA well in the life science industry.
Quarterly Revenue
$4.2B
2026-03
Revenue YoY Growth
+8.4%
YoY Comparison
Gross Margin
32.6%
Latest Quarter
Free Cash Flow
$2.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IQV Overvalued?
Given IQVIA's positive net income, the PE ratio is the primary valuation metric. The trailing PE is 28.50x, while the forward PE is 16.39x, implying the market expects significant earnings growth. The gap between trailing and forward PE suggests a 42.5% expected increase in earnings per share, reflecting optimism about future profitability.
PE
28.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 19x~44x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are notable, with a debt-to-equity ratio of 2.49x and interest expense of $192M in Q1 2026, which could pressure earnings if rates rise. The current ratio of 0.75 indicates potential liquidity issues, and the company's reliance on continued growth to justify its valuation is a concern. However, free cash flow of $2.545B TTM provides some cushion, and operating margins of 14.02% are healthy.
FAQ
The key risks include high financial leverage (debt-to-equity of 2.49x), which could strain cash flows if interest rates rise, and low liquidity (current ratio of 0.75). Competitive pressures from other CROs and technology disruption could slow growth, and the stock's beta of 1.175 makes it sensitive to market downturns. Additionally, the wide analyst target range suggests uncertainty about future performance.
The 12-month forecast is bullish, with a base case target of $240-$275 (50% probability), a bull case of $275-$300 (30% probability), and a bear case of $200-$240 (20% probability). The most likely scenario is moderate growth, with the stock reaching the average target of $275.17. Key assumptions include sustained revenue growth of 8-9% and stable margins.
IQVIA's trailing PE of 28.50x is above the market average, but the forward PE of 16.39x suggests the market expects significant earnings growth. Compared to peers, the PS ratio of 2.38x is moderate, and the PEG ratio of 6.34x indicates the stock may be overvalued relative to its growth rate. Overall, the valuation is fair if the company meets growth expectations, but it leaves little room for error.
IQVIA is a good buy for investors with a growth-oriented portfolio, given its strong buy consensus and 16.3% upside to the average target. However, the stock is trading near its 52-week high, and the high debt levels and low current ratio introduce risk. A prudent approach would be to wait for a pullback or enter with a long-term perspective, as the forward PE of 16.39x is reasonable if growth continues.
IQVIA is better suited for long-term investment, given its growth trajectory and the structural demand for clinical research services. The stock's beta of 1.175 and recent volatility make it less ideal for short-term trading, but its strong fundamentals and analyst optimism support a holding period of at least 2-3 years. Investors should monitor quarterly earnings and debt levels to ensure the thesis remains intact.